Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus reuteri MAK02L14R

What does the research say about Lactobacillus reuteri MAK02L14R?

2 health outcomes synthesised

Lactobacillus reuteri MAK02L14R is being studied for two health outcomes, primarily in pediatric populations. The strongest evidence, with moderate strength, supports its potential to reduce hospitalization duration, based on 3 studies in children with acute gastroenteritis and preterm neonates. No consistent effective dose has been identified across these studies.

Strongest evidence: The most robust finding is for reducing hospitalization duration, supported by 3 studies with moderate evidence strength. All 3 studies reported beneficial effects, though effect sizes varied: a large reduction of -10.77 days in preterm neonates and a small reduction of -0.54 days in children with acute gastroenteritis. No consistent dose range was reported.

Mixed or weaker evidence: For reducing duration of diarrhea, the evidence is low in strength and mixed. Of 3 studies, 2 found benefits (reductions of approximately 0.87 days and 32 hours in meta-analyses), but 1 recent RCT showed no significant effect, and most studies used the DSM 17938 strain, which may not be identical to MAK02L14R.

Effective dose patterns: No cross-cutting dose insights are available, as effective doses were not consistently reported in the studies for either outcome.

Population insights: Both outcomes focus on children: pediatric populations with acute gastroenteritis (under 5 years) and preterm neonates. The largest effect sizes were observed in preterm neonates for hospitalization duration.

Notable caveats: The evidence base is small, with only 3 studies per outcome, making conclusions preliminary. Publication bias may overstate benefits, as null-result studies are less likely to be indexed. Strain generalizability is uncertain, particularly for diarrhea outcomes, where most research used a different strain.

Frequently asked

  • What is Lactobacillus reuteri MAK02L14R good for according to research?
    Research suggests Lactobacillus reuteri MAK02L14R may help reduce hospitalization duration (moderate evidence from 3 studies, all showing benefit) and shorten diarrhea duration (low evidence, 2 of 3 studies showing benefit). These findings are based on pediatric populations with acute gastroenteritis and preterm neonates.
  • What dose of Lactobacillus reuteri MAK02L14R is typically used in studies?
    No consistent effective dose was reported across the studies for either reducing hospitalization duration or shortening diarrhea duration. Dose and form data were not consistently documented, and no specific range can be recommended from the current evidence.
  • Who benefits most from Lactobacillus reuteri MAK02L14R?
    The research primarily focuses on children under 5 years with acute gastroenteritis and preterm neonates. For hospitalization duration, preterm neonates showed the largest benefit (reduction of 10.77 days), while children with acute gastroenteritis had a smaller effect (0.54 days reduction).
  • Are there caveats or limitations in the research on Lactobacillus reuteri MAK02L14R?
    Yes, key caveats include a small evidence base (only 3 studies per outcome), publication bias (positive results more likely published), and for diarrhea outcomes, most studies used the DSM 17938 strain, which may not be identical to MAK02L14R. Conclusions should be considered preliminary.
  • Does Lactobacillus reuteri MAK02L14R help reduce hospitalization duration?
    Moderate evidence from 3 studies shows a beneficial effect, with all studies reporting reduced hospitalization duration. However, effect sizes varied substantially, from a small reduction of 0.54 days in children with acute gastroenteritis to a large reduction of 10.77 days in preterm neonates.
  • Does Lactobacillus reuteri MAK02L14R help reduce diarrhea duration?
    Low evidence from 3 studies is mixed: 2 meta-analyses found benefits (reductions of 0.87 days and 32 hours), but 1 recent RCT found no significant effect. Strain differences and inconsistency suggest results are not yet definitive.

Most-studied combinations with Lactobacillus reuteri MAK02L14R

most supplement research is combination research
  • Low evidence
    withLactobacillus reuteri UALre-16forReduced Hospitalization Duration· 3 studies

    All 3 studies report a beneficial effect of the combination of Lactobacillus reuteri MAK02L14R and Lactobacillus reuteri UALre-16 on reduced hospitalization duration, with effect sizes ranging from small to large. Two of the 3 studies reached statistical significance. Compared to the solo syntheses, the combination evidence does not show stronger or weaker effects—outcomes are similar, likely because both solo and combination studies tested the same underlying strains (DSM 17938) due to naming inconsistencies.

  • Daily Care Probiotic

    By Probulin

    4.7 (149 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $41.24
    		In
    Vitacost
    $50.29
    		In
    Vitamin Shoppe
    $-
    		Out

  • Total Care Soothe Probiotic + Prebiotic & Postbiotic

    By Probulin

    4.7 (25 reviews)
    In Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $35.99
    		In
    Vitacost
    $41.39
    		In
    Vitamin Shoppe
    $-
    		Out
Back to top